对FLT3抑制剂的耐药性涉及不同的分子机制,并减少了新的DNA合成
1Department of Chemistry and Biomedical Sciences, Linnaeus University, Kalmar, SE-39231, Sweden.
Biochemistry and biophysics reports
|February 3, 2025
概括
急性髓性白血病 (AML) 的耐药性源于多种机制,包括新型突变. 一种新的抑制剂,Chen-9u,有效地限制细胞生长,并防止AML模型中的耐药性发展.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 急性髓性白血病 (AML) 是一种具有挑战性的血液癌症,通常以FLT3突变为特征.
- 患者最初对FLT3抑制剂有反应,但药物耐药性限制了治疗成功.
研究的目的:
- 调查AML中药物耐药性的机制.
- 评估一种新型抑制剂Chen-9u对抗抗性AML细胞系的疗效.
主要方法:
- 产生了四个抗吉尔特里尼布或FF-10101.1的AML细胞系.
- 对抗性机制的分析,包括遗传突变和途径活性.
- 测试Chen-9u对抗性AML细胞生长的抑制作用.
主要成果:
- 每个抗性细胞系都表现出一种独特的抗性机制.
- 观察到FLT3降低和NRAS通路活性增加,由于CDK4活性降低,DNA合成减少.
- 确定的耐药性突变包括FLT3 (C695F,N701K),NRAS (G12C) 和可能的MYCN.
- 陈-9u抑制了细胞生长,并且没有通过这种抑制剂获得耐药克隆.
结论:
- AML细胞表现出对先进的FLT3抑制剂的多功能抵抗机制.
- 获得的耐药性影响细胞过程,如DNA合成,具有进化后果.
- 新型耐药细胞系作为研究AML耐药性的宝贵模型.
相关概念视频
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K


